Litcius/Paper detail

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Tianqing Chu, Runbo Zhong, Hua Zhong, Bo Zhang, Wei Zhang, Chunlei Shi, Jialin Qian, Yanwei Zhang, Qing Chang, Xueyan Zhang, Yu Dong, Jiajun Teng, Zhiqiang Gao, Huiping Qiang, Wei Nie, Yiming Zhao, Yuchen Han, Ya Chen, Baohui Han

2021Journal of Thoracic Oncology226 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineAdverse effectOncologyProgression-free survivalConfidence intervalHazard ratioGastroenterologyProgressive diseaseChemotherapyLung Cancer Research StudiesCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC | Litcius